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econdary bacterial infections among two cohorts of adults
n Brazil.
Methods: We created an initial decision model to eval-
ate the cost-effectiveness of PPV23 used as part of a
omprehensive pandemic plan in the United States. This
odel was adapted to reﬂect cost data from Brazil. Two
ohorts of 6 million Brazilian adults, aged 20-64, were
odeled: high-risk adults and critical workers. The model
ompares costs and disease outcomes associated with two
accination scenarios: PPV23 vaccination and no PPV23
accination. Outcomes are based on attack rates from
wo prior pandemic types: severe (1918) and moderate
1957/1968). PPV23 effectiveness was assumed to be 59%.
accine costs consisted of dose and administration costs.
osts are reported in 2008 Brazilian reals. Cost effective-
ess results are reported as incremental cost effectiveness
atios (ICER) using reals per Quality Adjusted Life Year
QALY).
Results: Under the assumption that no pandemic
nﬂuenza vaccine is available, PPV23 could prevent approx-
mately 15,000 pneumococcal disease cases in the high-risk
opulation during a severe pandemic and 9,000 cases dur-
ng a moderate pandemic. Among 6 million high-risk adults,
he ICERs comparing the PPV23 vaccination scenario ver-
us no PPV23 were estimated to be 1,700 reals per QALY
or a severe pandemic and 18,000 reals per QALY for a
oderate pandemic. Among 6 million critical workers aged
0-64, PPV23 could prevent 64,000 missed work days during
severe pandemic and 17,000 missed work days during a
oderate pandemic.
Conclusion: The cost effectiveness ratios for mass vac-
ination of high risk individuals as well as critical workers
sing PPV23 in Brazil to prevent secondary bacterial infec-
ions related to pandemic inﬂuenza fall within the range
enerally considered to be cost-effective; however, the
ost-effectiveness ratios depend on the severity of the pan-
emic.
oi:10.1016/j.ijid.2010.02.617
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mpact study of hepatitis B vaccination in Sikkim - A north
astern state of India
. Verma ∗, V. Gupta
Sikkim Manipal Institute of Medical Sciences, Gangtok,
IKKIM, India
Background: Sikkim is a small state of India which
ntroduced hepatitis B vaccination into its immunization
chedule. Sikkim is the ﬁrst state of India to introduce Hep-
titis vaccination in the year 2004. Hepatitis B coverage for
he state of Sikkim is approximately 10,000 children per year
nd immunization is done at 6, 10 and 14 weeks of age.
ooster dose has not been incorporated in the immunization
chedule. Since the time of introduction of immunization
o impact study has been done in the vaccinated children.
hether the children being vaccinated mount an adequate
ntibody response against the vaccine needs to be investi-
ated. An attempt was made to study the anti-HBs levels in
cross sectional study of children who received the vacci-
ation against Hepatitis B.
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Methods: 160 post vaccinated children and adolescents
ere included in the study. Only those who had completed
hree doses of the vaccination were included. Serum col-
ected was tested using a commercially available sandwich
LISA kit. The quality control criteria were fulﬁlled and the
ata was analyzed. Anti-HBs Levels below 10mIU/ml were
onsidered as non responders and levels above 10mIU/ml
ere considered as responders.
Results: 53.1% of the participants were males and 46.9%
ere females. Analysis of data revealed that 64.4% of the
opulation under study were responders and 35.6% were
on responders. Female participants who were non respon-
ers were greater than males (38.6%: 32.9%). No signiﬁcant
elation between age and response was seen.
Conclusion: The percentage of non-responders in the post
accination children was signiﬁcantly higher as compared
o most studies conducted in other countries. No study has
een done in India to see the impact of vaccination in chil-
ren. Females seem to be non responders as compared
o males contrary to some studies. Further studies need
o be conducted to investigate the cause of this anomaly.
resuming that India is on the verge of introducing uni-
ersal vaccination against HBV, preparedness to encounter
he problem of non responders to vaccination needs to be
ddressed and a strategy developed to counter it.
oi:10.1016/j.ijid.2010.02.618
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vaccine derived poliovirus case in an immunocompro-
ised argentinian child
.E. Burgos1,∗, S. Elkik1, P. Barbosa1, M. Oleastro1, C.
reire2, A. Parra1, M. Caparelli 3, C. Sarkis4
Hospital Garrahan, Buenos Aires, Argentina
Servicio de Neurovirosis Dpto. Virología. IENEI-NLIS ‘‘Dr.
arlos G. Malbran’’, Buenos Aires, Argentina
Ministerio de Salud, Buenos Aires, Argentina
Hospital Garrahan, Capital Federal, Argentina, Argentina
Background: Although poliomyelitis caused by wild-type
oliovirus has been almost eradicated, especially in devel-
ped countries, vaccine associated paralytic poliomyelitis
VAPP) cases still continue to occur in Latin American coun-
ries. In Argentina, where OPV routine immunization policy
s ongoing, the last wild poliovirus (WPV) case was registered
n 1984. Since then, the several polio cases reported were
APP and Vaccine Derived Poliovirus (VDPV) (ﬁrst iVDPV case
as detected in 1998).
Methods: To report a polio case caused by a VDPV in an
mmunodeﬁcient patient diagnosed with polyclonal agam-
aglobulinemia.
Results: In May 2009 a 15 month-old patient was hospi-
alized in our institution for acute ﬂaccid monoparesis in his
eft lower limb with areﬂexia, with residual paralysis 60 days
fter onset. The patient had a history of recurrent infections
sepsis meningitis and pneumonia).Vaccination calendar was
ompleted for his age (DPt/Hib-HB & OPV: 3 doses). The
hild received OPV3, 8 months before. LCR 8 cells/prot
5mg/100mL/Glu 50mg/ml with negative cultures (bac-
eria -mycobacterium, fungi). EMG showed pre-ganglionic
njury. Spine MRI showed focal intramedullary cone and
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Although immunoglobulin measurements are a surrogate
marker of immunity, there is no reliable predictor of
whether a HIV-positive patient will mount adequate sero-14th International Congress on Infectious Diseases (ICID) Abs
lower thoracic spinal cord with hyperintense signal in T2
left hemicord. The major capsid protein (VP1) of the Sabin
virus T1 isolated in feces showed a 96.5% genetic similarity
to Sabin 1 vaccine strain (a 3.5% genetic divergence in this
region).
Conclusion: The occurrence of iVDPVs appears to be very
rare; the majority of patients stopped excretion of the virus
after a certain period or have died. The overriding factor for
the emergence of all VDPVs is the same as for WPV circula-
tion, i.e., low routine OPV coverage rates in children. Thus,
a community can become susceptible to the emergence of
all types of VDPV producing an impact in the public health
of the population. New polio vaccination strategies should
be considered to avoid future VDPV cases and to be aligned
WHO endgame strategies.
doi:10.1016/j.ijid.2010.02.619
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Inﬂuenza vaccine: Immunization rates, knowledge, atti-
tudes and practice of health care workers in Iran in
2008/09
Z. Khazaeipour1,∗, N. ranjbar novin2, N. Hoseini 1
1 Health deputy of Tehran University of Medical Science,
Tehran, Iran, Islamic Republic of
2 Research Development Centerof Imam Khomeini Hospital
Complex, tehran, Iran, Islamic Republic of
Background: Inﬂuenza is an important cause of excessive
morbidity and mortality each winter. Its short incubation
period and efﬁcient transmission from person to per-
son makes inﬂuenza hazardous to the patients and staff
in healthcare facilities. The aims of this study were to
determine inﬂuenza vaccine coverage and evaluate the
knowledge, attitudes and practice about inﬂuenza and vac-
cine.
Methods: This study was a cross-sectional survey that was
performed between October 2008 and February 2009 in 139
health care workers (HCWs) of health deputy of Tehran Uni-
versity of medical science, Tehran, Iran. They received a
self-administered questionnaire and then the research assis-
tant waited to collect them.
Results: The response rate to the questionnaire
was 96.5%. The inﬂuenza vaccination coverage for the
2008—2009 seasons was 66.9% (range, 45% to 62%). Most
HCWs (80.6%) had received an inﬂuenza vaccination in the
past, and 65.4% intended to receive vaccination in the
future year. The main reason given for being immunized
was effectiveness of inﬂuenza vaccine (51.4%). The main
reason given for not being immunized was concerned about
sideeffects (23.1%). The knowledge score for the 35 items
ranged from 0 to 34 (mean 17.37). Mean knowledge scores
differed between courses. There was no signiﬁcant differ-
ence in mean knowledge scores between female and male
(P > 0.05) None of independent variables included age, sex,
marital status, having children aged)16 years and courses
were signiﬁcant predictors of taking inﬂuenza immuniza-
tion.
Conclusion: In our study, despite high coverage rate of
inﬂuenza vaccination in comparison with other studies, we
would expect higher rate because of free vaccine availabil-
l
ats e451
ty. The study results indicate that there is the need for
n-going education of Inﬂuenza disease, vaccine action and
enters for Disease Control and Prevention (CDC) recom-
endation among HCWs to increasing vaccination rates.
oi:10.1016/j.ijid.2010.02.620
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ariable serological response to PPV in HIV-positive
atients — A need to review pneumococcal boost-prime
trategies?
. Brown1,∗, C. Rock2, C. Ní Bhuachalla1, T. Coulter1, C.
owling1, C. Bergin1
St. James’s Hospital, Dublin, Ireland
Cork University Hospital, Dublin, Ireland
Background: International guidelines recommend 23-
olyvalent polysaccharide pneumococcal vaccination (PPV)
or HIV-positive patients with CD4 >200 cells/mm3. His-
orical data shows suboptimal response to vaccination in
IV-positive patients when measured by pneumococcal-
peciﬁc IgG and vaccine serotype-speciﬁc IgG2. There is
ittle data to support the efﬁcacy of vaccination in consis-
ently producing serological response, or assessing the role
f conjugate vaccine in adults.
Methods: In a cross-sectional study, 82 random sam-
les were taken from HIV-positive outpatients. The samples
ere assessed for pneumococcal IgG and IgG2. IgG2 lev-
ls >69g/L are considered good serological evidence of
esponse in the absence of baseline titres with which to com-
are post-vaccination response. Demographic, vaccination
nd laboratory data was recorded. Results were analysed
sing Fisher’s exact test and two-tailed p values with Graph-
ad InStat.
Results: Four patients were excluded with no prior his-
ory of pneumococcal vaccination, and two for incomplete
ata. The remaining 76 patients(M = 47, F = 29) were aged
etween 21 and 71 years (mean = 39.1yrs, SD 9.86) at the
ime of ﬁrst vaccination. Twenty-six patients (34%) received
ooster. Sixty-one patients (80%) were taking ART at the time
f sampling. Thirteen patients (17.1%) had vaccine serotype-
peciﬁc IgG2 titre ‘‘69g/L at the time of sampling.
chieving an IgG2 titre’’ 69g/L was not associated with
ny of the measured variables —– age < vs ‘‘35 yrs at vaccina-
ion(p = 0.54); male vs female sex(p = 0.54); CD4 count <200
s’’ 200 cells/mm3 at ﬁrst vaccination(p = 0.58); CD4 count
350 vs >350 cells/mm3 at ﬁrst vaccination(p = 1.00); CD4
ount <350 vs >350 cells/mm3 at time of sampling(p = 0.34);
RT at sampling time vs no ART(p = 1.00); single vs boosted
oses(p = 0.19); <234 weeks (4, years) since vaccination vs
‘234 weeks(p = 0.37).
Conclusion: In the HAART era only a minority of patients
how adequate levels of vaccine serotype-speciﬁc IgG2
egardless of time since vaccination or booster dosing.ogical response to PPV. Further studies are needed to
ssess the nature of response to PPV, alternative conju-
